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Objective: To understand the relationship across the glycaemic spectrum, with brain 
health. We hypothesised that individuals with increasingly higher HbA1c would be 
more likely to have worse brain health outcomes in comparison to normoglycaemic 
individuals. 
Methods: UK Biobank participants. HbA1c and diabetes diagnosis define baseline 
glycaemic categories. Outcomes: incident vascular dementia (VD), Alzheimer’s 
dementia (AD), hippocampal volume (HV), white matter hyperintensity (WMH) 
volume, cognitive function and decline. Reference group: normoglycaemic 
individuals (HbA1c 35-<42 mmol/mol).  
Results: Pre- and known diabetes increased incident VD, (HR 1.54, 
95%CI=1.04;2.28 and 2.97, 95%CI=2.26;3.90). Known diabetes increased AD risk 
(HR 1.84, 95%CI=1.44;2.36). Pre- and known diabetes elevated risks of cognitive 
decline (OR 1.42, 1.48;2.96 and 1.39, 1.04;1.75). Pre-diabetes, undiagnosed and 
known diabetes conferred higher WMH volumes (4%, 26%, 5%,) and lower HV 
(22.4mm3, 15.2mm3, 62.2mm3). Low-normal HbA1c had 2% lower WMH volume and 
13.6mm3 greater HV.  
Interpretation: Pre and known diabetes increase VD risks; known diabetes increases 
AD risk. Low-normal HbA1c associates with more favourable neuroimaging 
outcomes. Our findings may have implications for cardiovascular medication in 
hyperglycaemia for brain health.  
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Type-2 diabetes and, more generally, hyperglycaemic states, have been associated 
with poorer cognitive function (such as learning and memory)1,2, increased risk of 
dementia2,3 and alterations in key brain structures, particularly the hippocampus4. It 
is also important to explore how low-normal levels (vs. normal glycaemic levels) of 
glycated haemoglobin (HbA1c) relate to brain health outcomes, which has not been 
investigated in a population-based study, to date. A previous paper explored the 
cross sectional association between baseline diabetes and two cognition measures 
in the UK Biobank (reaction time and visual memory)5. The authors found that 
diabetes was associated with poorer scores on the reaction time test, but 
paradoxically, better scores on the visual memory test. They did not explore other 
brain health outcomes or lesser glycaemic states. 
 
Memory loss is the most conclusively reported adverse effect of hyperglycaemia on 
cognitive function6, yet hyperglycaemia also associates with worse processing 
speed, attention, concentration and executive functions 7. Hippocampal atrophy is a 
crucial feature of age-related memory loss and the hippocampus is reportedly more 
vulnerable to the neurotoxic consequences of diabetes8,9. Evidence relating diabetes 
to the presence and progression of white matter hyperintensities is equivocal10, but 
some research suggests that those with diabetes have greater volumes of white 
matter hyperintensities11,12. Although there have been numerous studies in this area, 
the role of glycaemia in brain health across the entire glycaemic spectrum remains 
unclear, in particular no studies have investigated how lesser hyperglycaemic states 
relate to these outcomes, as most studies have focused on diagnosed diabetes only. 
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Thus, our aim was to investigate, in a single large-scale study, the associations 
between five glycaemic states across the entire spectrum (low-normal HbA1c, 
normoglycaemia, pre-diabetes, undiagnosed diabetes and known diabetes) and a 
breadth of brain health outcomes including: Alzheimer’s dementia (AD) risk, vascular 
dementia (VD) risk, baseline cognitive function and cognitive decline, hippocampal 
volume, and white matter hyperintensities volume in the UK Biobank. We 
hypothesised that those with increasingly higher HbA1c would have worse outcomes 




Full details of the UK Biobank (UKB) cohort have been described elsewhere13. 
Briefly, UKB consists of ~500,000 men and women from the general UK population 
between 2006-2010, aged between 40 and 69 years of age at baseline. Participants 
have detailed phenotype data on physical (subjective and objective), mental and 
lifestyle measures, as well as linkages to routinely collected data (e.g. deaths, 
hospital admissions and cancer registers). Figure 1 depicts our study design.  
 
Informed consent and ethical approval 
UK Biobank received ethical approval from the North West Multi-centre Research 
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Type-2 diabetes mellitus (diabetes) 
Exposure status was defined using baseline data on diabetes and HbA1c. Diabetes 
was  defined using an algorithm of self-report doctor diagnosis and/or medication; 
this algorithm has been validated against primary care data14  HbA1c assays were 
performed using five Bio-Rad Variant II Turbo analysers, outlined in detail in the UK 
Biobank protocol15. In this study, values greater than 200 mmol/mol were excluded 
(n=5), as they were considered to be outliers and clinically implausible. For our 
analyses we divided participants into the following categories: known diabetes, 
undiagnosed diabetes (≥48 mmol/mol), pre-diabetes (42-<48 mmol/mol), 
normoglycaemic (≥35 & <42 mmol/mol), and low HbA1c (<35 mmol/mol)  –  based on 
criteria by Ginde and colleagues 16.  
 
Dementia  
Dementia at baseline was captured using ICD-10 codes in linked hospital episode 
statistics (HES) data. Incident dementia was algorithmically defined with the method 
described in Wilkinson et al. 17, which was based on linked UK hospital admission, 
mortality and primary care data. Here we focus on vascular dementia (n=412) and 
AD (n=749); frontotemporal dementia cases were excluded (n=95). 
 
Structural brain MRI outcomes 
Structural brain MRI scans have been performed in a subsample of UKB participants 
using standard protocols, details of which are published18. Post-processed measures 
(provided by UKB) used in this study included: hippocampal volume (mm3), 
normalised for head size and total volume (mm3) of white matter hyperintensities 
(WMH, mm3). WMH volume was log-transformed as it was positively skewed; thus, 
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we report exponentiated betas for this outcome to ease interpretation. The total 




For cognitive function we pragmatically selected two measures with adequate 
sample sizes to represent distinct cognitive domains, namely reaction time (RT) and 
visual memory. In the visual memory test, respondents had to identify matches from 
six pairs of cards after memorising their positions on the screen. The number of 
incorrect matches (errors made) was then recorded, whereby a higher number 
indicates poorer visual memory. RT was measured as the mean time (in 
milliseconds) taken to correctly identify matches from 12 rounds of the card game 
‘Snap’, where a longer time indicates slower RTs. As per Lyall et al., (2016)19 
reaction time (RT) was transformed using a log transformation (ln) and visual 
memory was transformed using an ln+1 equation (due to zero-value inflation). The 




Using data from a subset of participants with both baseline and follow-up measures 
of cognitive function, cognitive decline was determined using the Standardised 
Regression Based method20. This included regressing follow-up visual memory on 
baseline visual memory, age, sex, years of education, and time between the two 
assessments. Subsequently, those whose standardised residual was greater than 
(absolute value) 1.96 (0.05 type-1 error rate) were assigned as having cognitive 
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decline. Only a proportion of the UKB participants had follow-up visual memory data 
and complete covariate data (n=18,809).  
 
Covariates  
Demographics such as age (years), sex, ethnicity (White European, Asian/Asian 
British, Black/Black British, Other), deprivation (quintiles of Townsend deprivation 
index, from ‘least deprived’ to ‘most deprived’), and educational attainment (derived 
as years of full-time education completed, as per qualifications based on coding from 
the International Standard Classification of Education 21) were included. Health 
behaviours included smoking status (never, current smoker and ex-smoker). Health 
measures included body mass index (BMI) in kg/m2, baseline cardiovascular disease 
(CVD – assigned using baseline self-report, nurse interview and linked hospital 
inpatient data between 2006 and 2010), anti-hypertensive medication and statin use; 
medications were captured and classified according to British National Formulary 
(BNF) chapters.  
 
Exclusion criteria 
Those who had AD, vascular or frontotemporal dementia or cognitive impairment 
prior to their recorded date of baseline assessment (2006-2010), as captured by self-
report, nurse interview or HES were excluded.  
 
Missing data 
There were missing data across several variables, all of which had <10% 
missingness and for this reason we used complete case analysis for this study. The 
missing data were as follows: ethnicity n=2275, BMI n=3260, reaction time n=5776, 
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visual memory n=4627, deprivation n=623, smoking n=1918, HbA1c n=34,594, 
antihypertensives and statins n=8589, educational attainment n=9133.  
 
Statistical analyses 
Analyses were performed in RStudio, version 1.1.456 and STATA version 15.   
 
Modelling approach  
Cross-sectional cognitive function and structural brain analyses 
In the cross-sectional analyses, glycaemia was entered as an exposure and four 
linear regressions were fitted to explore the relationship with baseline cognition 
outcomes (reaction time and visual memory). Model 1 consisted of adjustment for 
demographic measures (age + sex + deprivation + educational attainment + 
ethnicity), Model 2 was additionally adjusted for standard cardiovascular risk factors 
(smoking + BMI + CVD + anti-hypertensives + statins). Our modelling approach was 
identical for structural brain outcomes (hippocampal volume and volume of WMH).  
 
Cognitive decline analyses  
Only 4% of UKB participants underwent follow-up cognition testing, so our analyses 
of cognitive decline were restricted to this sub-population. The same models were 
fitted as in the analyses of baseline data. Logistic regression was used to investigate 
the association between glycaemia and binary cognitive decline, with the same 
modelling strategy as above.  
 
Dementia analyses  
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Cox proportional hazards models were used to examine the relationships between 
glycaemia and a) AD and b) vascular dementia. The time scale was time since study 
entry and participants were followed up until 31 March 2017. The same modelling 
strategy was used, as described above. The proportional hazards assumption was 
assessed using the global test to evaluate the interaction of each covariate with time, 
alongside Schoenfeld residuals.    
 
RESULTS   
Sample characteristics 
449,973 individuals were included in the study, of whom 210,309 had low-normal 
HbA1c levels, 198,969 had normoglycaemic levels, 15,229 had pre-diabetes, 3279 
had undiagnosed diabetes and 22,187 had known diabetes. Those with prediabetes 
and known diabetes were older than the other groups. Those with diabetes 
(undiagnosed and known) were more likely to be ex-smokers, reside in the most 
deprived quintile and have higher BMIs (Table 1). Those with known diabetes were 
most likely to be taking antihypertensives and statins at baseline and had the highest 
prevalence of CVD.  
  
Glycaemia and AD, and vascular dementia (VD) 
We do not present results from the undiagnosed diabetes group, as the number of 
cases for both AD and VD was <20. Pre-diabetes and low-normal HbA1c were not 
associated with AD in a basic or fully-adjusted model (Fig 2). However, known 
diabetes was strongly associated with excess AD risk on minimal adjustment and 
this remained robust in a fully-adjusted model (HR 1.84, 95%CI=1.44;2.36). People 
with pre-diabetes had elevated risks of VD, as did those with known diabetes (HR 
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1.75, 95% CI=1.19;2.59 and HR 3.73, 95% CI=2.90;4.80, respectively) (Fig 2), but 
low-normal HbA1c was not associated with VD (Fig 2).   
 
Adjustment for health-related measures attenuated associations between glycaemia 
and VD, but this remained large at 54% increased risk of VD in pre-diabetes and 
almost 3-fold excess risk in known diabetes. The key factor responsible for 
accounting for excess risk for both pre-diabetes and known diabetes in multi-variate 
models was antihypertensive therapy. Model 1 HRs were 1.75 (95% CI=1.19;2.59) 
and 3.73 (95% CI= 2.90;4.80) for pre-diabetes and known diabetes, respectively. 
Additional adjustment for antihypertensive therapy only (in addition to Model 1), 
resulted in HR 1.61 (95% CI= 1.09; 2.39) for pre-diabetes and 3.04 (95% CI= 
2.34;3.95) for known diabetes. We also performed sensitivity analyses for both AD 
and VD in which we included both systolic blood pressure (SBP) alongside 
antihypertensives in our multiply-adjusted models. However, as the results remained 
qualitatively the same, albeit with less precision due to a smaller number of cases, 
we do not present these estimates.  
 
Glycaemia and hippocampal and white matter hyperintensity volumes 
Low-normal HbA1c was associated with lower WMH volume, and greater 
hippocampal volume than normoglycaemic individuals, while pre, undiagnosed and 
known diabetes were associated with higher WMH volume and lower hippocampal 
volume (Fig 3). Multivariable adjustment, specifically when antihypertensive therapy 
was added, markedly attenuated associations for pre and known diabetes, but less 
so for undiagnosed diabetes, for WMH volume only. Thus pre-diabetes, undiagnosed 
diabetes and known diabetes were associated with greater WMH volumes (4%, 26% 
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and 5% respectively), and smaller hippocampal volumes (22mm3, 15mm3, 62mm3) in 
fully-adjusted models. Those with low-normal HbA1c had 2% lower WMH volume, 
and 14mm3 larger hippocampal volumes than normoglycaemic individuals. 
 
Glycaemia, baseline reaction time and visual memory, and cognitive decline  
Those with low-normal HbA1c had reaction times that were no different to the 
normoglycaemic group; however, both undiagnosed and known diabetes were 
associated with a 2% slower reaction time, while pre-diabetes was related to 1% 
slower reaction times on multivariate adjustment (Table 2). Low-normal HbA1c and 
undiagnosed diabetes were not associated with visual memory scores, but those 
with known diabetes made 3% fewer errors, compared to the normoglycaemic group 
(Table 2). In Model 1 (demographics) pre-diabetes and known diabetes were 
associated with somewhat greater risk of cognitive decline (Fig 4), but the 95% 
confidence intervals around the odds ratios were wide. However, in the fully-adjusted 
model these associations became more pronounced and pre-diabetes and known 
diabetes related to a 42% and 39% increased risk of cognitive decline, respectively. 
Upon close inspection of the model, we observed a strong relationship between BMI 
and cognitive decline, which suggested that those with a higher BMI were less likely 
to suffer from cognitive decline, OR 0.97 (95%CI = 0.95; 0.99). This remained 
identical upon multivariate adjustment for age, sex, deprivation, smoking, statins, 
antihypertensives and CVD.  
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In this large sample of middle aged adults we report four key findings; first, people 
with pre-diabetes and known diabetes have excess risks of clinically important 
outcomes (cognitive decline and dementia), second, that a key determinant of the 
excess risk of vascular dementia in association with hyperglycaemia is 
antihypertensive medication, third, associations between hyperglycaemia and 
dementia are stronger for vascular than Alzheimer’s dementia and finally, that low-
normal levels of glycaemia may be somewhat beneficial in relation to subclinical 
measures of brain health, such as certain neuroimaging parameters.  
 
It is striking that pre-diabetes and known diabetes both increase the risk of VD, 
cognitive decline and to a slightly lesser extent AD, in comparison to 
normoglycaemic individuals. A recent meta-analysis suggests excess dementia risk 
in pre-diabetes 22 but most studies do not make a direct comparison to people with 
established diabetes, and have been restricted by small numbers of events. Risks of 
cognitive decline have been more extensively studied, with the majority identifying 
pre-diabetes as a high-risk state, though few suggest that risks are close to 
established diabetes 23,24. This has important implications for intervention. With 
greater numbers of individuals surviving to older age, avoidance or at least 
postponement of dementia is an increasing therapeutic concern, and, much like the 
finding of excess CVD risks in people with pre-diabetes 25,26, prompts consideration 
of identification and early intervention in such individuals.   
 
Mid-life hypertension increases dementia risk 27,28 and is associated with greater 
WMH volumes 29. A recent review of antihypertensive therapy and cerebral small 
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vessel disease (SVD) trials showed that antihypertensive therapy protects against 
progression of white matter hyperintensities 30. That we show attenuation of risk of 
both VD and WMH volume on adjustment for the greater use of antihypertensive 
medication in hyperglycaemic states can superficially be interpreted as treatment 
having adverse, not beneficial, effects. However, we suggest that, in this context, 
receipt of antihypertensive medication is acting as an indicator of longstanding 
untreated elevated blood pressure and that therefore, treatment is being instituted 
too late. This is supported by a recent study which suggests that treatment for 
hypertension should begin as early as the third decade to potentially reduce risk of 
disease and early mortality 31. Early adulthood blood pressure, measured at around 
age 43 years, is also more strongly related to WMH volumes at age 70 than blood 
pressure measured throughout middle age, or indeed contemporaneous with WMH 
volume assessment 32, highlighting the importance of elevated blood pressure even 
before middle age. The role of even modest elevations in blood pressure, blood 
pressure trajectories from young adulthood, and early blood pressure lowering 
intervention, requires exploration in the context of reducing risks of brain pathology.  
 
We show associations between hyperglycaemic states, from pre-diabetes to 
established diabetes and all of our outcomes, but these appear somewhat stronger 
with VD and WMH volume than AD and hippocampal volume, as the latter were 
resistant to adjustment for CVD risk factors. This is in line with evidence that 
diabetes is associated with greater WMH volume 11,12 and a study in the Genetics of 
Diabetes Audit and Research in Tayside Scotland (GoDARTS) case-control sample, 
which revealed that those with diabetes had more than a two-fold excess risk of VD, 
but there was no association with AD 33. However, discrimination between VD and 
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AD remains challenging and there have been no studies to date, that have 
investigated the associations lesser hyperglycaemic states and VD/AD in a single 
study. That we observed a stronger association between glycaemia and VD and 
WMH, as opposed to hippocampal volume and AD is perhaps suggestive of two 
distinct, yet related neurological and vascular pathways. This is in turn is supportive 
of a ‘two-hit hypothesis’, which has gained popularity more recently 34. Briefly, a 
combination of genetic, environmental and vascular risk factors results in 
neurovascular dysfunction, alongside damage to arterioles, small arteries and brain 
capillaries, either through pathways independent of amyloid-ß (hit one) and/or 
pathways dependent on amyloid-ß (hit two). These pathways converge on blood 
vessels and  can synchronously or independently cause the neuronal dysfunction 
associated with dementia 34. Just how these pathways act synergistically or 
independently remains unclear.  
    
Another novel finding is that low-normal HbA1c levels were associated with greater 
hippocampal volume and lower WMH volume, in comparison with normoglycaemic 
individuals. Participants with low-normal HbA1c tended to be younger and healthier 
than the other groups, were less likely to be smokers, less likely to reside in higher 
quintiles of deprivation, had lower prevalence of baseline CVD and fewer of them 
were on statins or antihypertensives. Adjustment for these factors somewhat 
attenuated the relationship between low-normal HbA1c and white matter 
hyperintensity volumes, but this was not the case for hippocampal volume. This may, 
once again, suggest that distinct mediators operate in the association between 
glycaemia and AD and atrophy of the brain, compared to factors that mediate the 
relationship between glycaemia and vascular brain damage. Although our findings 
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preclude us from any temporal or causal claims about this association, it is possible 
that in middle-aged adults without diabetes (~54 years) HbA1c levels below 35 
mmol/mol could confer some protection against hippocampal atrophy, as well as the 
presence of white matter hyperintensities. Our findings also indicate that pathways to 
brain health in association with persistently lower HbA1c in people without diabetes 
are likely different to those with bouts of hypoglycaemia in people with diabetes.  
We also observed that pre-diabetes associates with 1% slower reaction times, 
whereas undiagnosed and known diabetes were associated with 2% slower reaction 
times. Our finding is supported by an early study of diabetes patients who performed 
slower on a reaction time task, in comparison to age-matched controls 35. We show 
that there are apparent effects at least cross-sectionally, in pre-diabetes and 
undiagnosed diabetes, in comparison to normoglycaemia. The association we 
observed between glycaemia and visual memory was somewhat paradoxical, as 
known diabetes was associated with 3% fewer incorrect matches on this task. It is 
possible, however, that other factors common to individuals with diabetes (e.g. 
effects of medication to control glycaemia) could confer some protection against 
poorer visual memory.   
 
In the 18,809 participants who had follow-up visual memory data we found that pre-
diabetes and known diabetes conferred a 42% and 39% excess risk of cognitive 
decline on multivariate adjustment. While only 32 people with pre-diabetes, and 42 
people with known diabetes experienced cognitive decline during the study follow-
up, the fact that both hyperglycaemic states were associated with adverse effects on 
brain health compared to normoglycaemic individuals adds confidence to our 
conclusion that hyperglycaemia adversely effects cognitive function, in line with 
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previous observations 36. We observed that adjustment for BMI substantially 
increased the odds ratios from our demographics-only model, such that individuals 
with a higher BMI were less likely to suffer from cognitive decline. This may relate to 
the ‘obesity paradox’, whereby those with higher BMIs have lower mortality rates 
than normal weight individuals, for which several explanations have been proposed 
36.  
 
Our study possesses some important strengths. UK Biobank is one of the largest 
studies to have data on HbA1c across the entire glycaemic spectrum, cognitive 
function, dementia sub-types and structural brain MRI measures. We used validated 
algorithms to define diabetes and dementia, but we acknowledge that completely 
accurate diagnoses of dementia in particular, remain a challenge. However, the 
visual memory test used for follow-up (and thus to define cognitive decline) did not 
show good reliability (r=0.16) in UKB. UKB had a low response rate and as a result, 
may suffer from selection bias, which could mean participants were less likely to 
have cognitive problems at study inception. Thus, it is possible that the association 
between glycaemia and our outcomes may have been underestimated.  
 
In conclusion, we show that both pre-diabetes and known diabetes are detrimental in 
terms of vascular dementia risk and cognitive decline and these excess risks appear 
to be driven by treated hypertension. Somewhat weaker associations with AD and 
hippocampal volumes indicate pathological mechanisms beyond standard CVD risk 
factors, in association with hyperglycaemia, that affect brain health. Our findings of 
potential beneficial effects of low-normal HbA1c on white matter and hippocampal 
volume are intriguing and require further investigation.  
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Fig. 2. Association between glycaemia and incident Alzheimer’s and vascular 
dementia in UK Biobank (N=449,973) 
 
Note. Model 1= adjusted for age + sex + deprivation + ethnicity + educational 
attainment, Model 2= Model 1 + BMI + CVD + statins + antihypertensives + smoking, 
95%CI = 95% confidence interval.  
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Fig. 3. Association between glycaemia and, hippocampal and white matter 
hyperintensity volumes in a UKB subsample (N=18,578) 
 
Note. Model 1= adjusted for age + sex + deprivation + ethnicity + educational 
attainment, Model 2= Model 1 + BMI + CVD + statins + antihypertensives + smoking, 
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Fig. 4. Association between glycaemia and cognitive decline in a UKB subsample 
(N=18,809) 
 
Note. Model 1= adjusted for age + sex + deprivation + ethnicity + educational 
attainment, Model 2= Model 1 + BMI + CVD + statins + antihypertensives + smoking, 
95%CI = 95% confidence interval.  
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Table 1. Baseline characteristics and outcomes across the glycaemic spectrum, N= 
449,973  










Age - Mean(SD) 54.4(8.2) 58.1(7.5) 60.1(6.8) 58.5(7.3) 59.8(7.1) 
Men N(%) 94447 (45) 87597 (44) 7205 (47) 1967 (60) 13862 (62) 
Education years - Mean(SD) 15.5(4.9) 14.7(5.2) 13.8(5.3) 13.9(5.2) 13.7(5.3) 
Ethnicity N(%)      
White European 204186 (97.1) 189305 (95.1) 13435 (88.2) 2837 (86.5) 19880 (89.6) 
South Asian 1514 (0.7) 2904 (1.5) 519 (3.4) 165 (5) 1003 (4.5) 
African Caribbean 1499 (0.7) 2636 (1.3) 670 (4.4) 148 (4.5) 558 (2.5) 
Mixed or other 3110 (1.5) 4124 (2.1) 605 (4) 129 (3.9) 746 (3.4) 
Deprivation N(%)      
Least deprived 44865 (21) 40688 (20) 2583 (17) 501 (15) 3354 (15) 
2nd least deprived 43902 (21) 40490 (20) 2769 (18) 531 (16) 3728 (17) 
Median deprivation level 42853 (20) 40498 (20) 2824 (18) 606 (18) 4105 (18) 
2nd most deprived 41925 (20) 39377 (20) 3198 (21) 676 (21) 4672 (21) 
Most deprived 36764 (17) 37916 (19) 3855 (25) 965 (29) 6328 (28) 
Smoking N(%)      
Never smoker 148515 (71) 127610 (64) 8539 (56) 1824 (56) 12188 (55) 
Current smoker 16908 (8) 24476 (12) 2474 (16) 500 (15) 2386 (11) 
Ex-smoker 44886 (21) 46883 (24) 4216 (28) 955 (29) 7613 (34) 
BMI kg/m2 - Mean(SD) 26.5(4.2) 27.6(4.7) 30.3(5.5) 32(5.7) 31.4(5.8) 
HbA1c mmol/mol - 
Mean(SD) 
32.1(2.3) 37.4(1.8) 43.8(1.5) 58.7(15.1) 53.1(13.9) 
HbA1c % - Mean(SD) 5.1(0.2) 5.6(0.2) 6.2(0.1) 7.5(1.4) 7(1.3) 
 
Cognitive function at baseline 
RT - milliseconds -Mean(SD) 545.7(108.9) 565.4(116) 584.1(129.3) 579.5(127) 587.5(129.6) 
VM - incorrect matches - 
Mean(SD) 
4.0 (3.2) 4.3 (3.4) 4.4 (3.6) 4.4 (3.5) 4.3 (3.6) 
 
Incident dementia 
AD N(%) 267 (0.1) 349 (0.2) 32 (0.2) 5 (0.2) 96 (0.4) 
VD N(%) 110 (0.1) 165 (0.1) 30 (0.2) 5 (0.2) 102 (0.5) 
Statins N(%) 18450 (9) 36447 (18) 5195 (34) 983 (30) 17022 (77) 
Antihypertensives N(%) 28757 (14) 43287 (22) 5731 (38) 1127 (34) 14435 (65) 
Baseline CVD N(%) 7974 (4) 14559 (7) 2364 (15) 450 (14) 4803 (22) 
 
Follow-up sub-sample of n=18,809 
Cognitive decline N(%) 375 (4) 361 (4) 32 (6) 8 (0.2) 42 (6) 
 
Imaging sub-sample of n=18,578 
n 9978 7669 400 79 452 
WMHV mm3 -Median(IQR) 2268 (3187) 2965 (4449) 3948 (5216) 4275 (7183) 4089 (6252) 
HV mm3 - Mean(SD) 3884.3 (432.3) 3817.3 (432.1) 3766.3 (453.3) 3864.3 (570.9) 3766.1 (445.9) 
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Note. BMI=body mass index (kg/m2), HbA1c= glycated haemoglobin, 
CVD=cardiovascular disease, RT= reaction time, VM= visual memory, VD= vascular 
dementia, AD= Alzheimer’s disease, WMHV= white matter hyperintensity volume, 
HV= hippocampal volume, AD= Alzheimer’s disease, IQR= interquartile range, low 
HbA1c <35 mmol/mol, normoglycaemic 35-<42 mmol/mol, pre-diabetes 42-<48 
mmol/mol, undiagnosed diabetes ≥48 mmol/mol, SD=standard deviation.  
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Table 2. Association between glycaemia and baseline cognitive function, N=449,973 
 Reaction time Visual memory 
Group Expß (95% CI) Expß (95% CI) 
Model 1  
Low HbA1c 1.00 (0.99;1.00) 1.00 (1.00;1.00) 
Prediabetes 1.01 (1.01;1.01) 0.99 (0.98;1.00) 
Undiagnosed T2DM 1.01 (1.01;1.02) 0.99 (0.96;1.01) 
Known T2DM 1.02 (1.01;1.02) 0.97 (0.96;0.98) 
Model 2 
Low HbA1c 1.00 (0.99;1.00) 1.00 (0.99;1.00) 
Prediabetes 1.01 (1.01;1.01) 1.00 (0.98;1.01) 
Undiagnosed T2DM 1.02 (1.01;1.02) 1.00 (0.98;1.03) 
Known T2DM 1.02 (1.01;1.02) 0.97 (0.96;0.98) 
Note. Model 1= adjusted for age + sex + deprivation + ethnicity + educational 
attainment, Model 2= Model 1 + BMI + CVD + statins + antihypertensives + smoking. 
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